Table 3.
Patterns of melanoma recurrence grouped according to the method of pelvic lymph node dissection (open or robot-assisted)
| oPLND (n = 8) (2012–2016) |
rPLND (n = 14) (2017–2023) |
Pa | |
|---|---|---|---|
| Median follow-up, months | |||
| Median | 25.7 (6.16–87.7) | 21.1 (14.0–30.5) | 0.137b |
| Systemic therapy | |||
| Therapy before PLND | 37.5 (n = 3) | 53.8 (n = 7) | 0.571 |
| Therapy after PLND | 75.0 (n = 6) | 92.9 (n = 13) | 0.240 |
| Lines of post op systemic therapy | 0.588 | ||
| None | 25.0 (n = 2) | 7.1 (n = 1) | |
| Adjuvant therapy | 37.5 (n = 3) | 57.1 (n = 8) | |
|
Multiple (adjuvant and on progression) |
37.5 (n = 3) | 35.7 (n = 5) | |
| Melanoma recurrence | 0.836c | ||
| Distant recurrence | 75.0 (n = 6) | 71.4 (n = 10) | |
| Pelvic recurrence | 37.5 (n = 3) | 42.9 (n = 6) | |
| No recurrence | 12.5 (n = 1) | 14.3 (n = 2) | |
aχ2 test; bunpaired t test; cχ2 for trend test